In a squeaker, Veru’s COVID-19 drug loses split decision at FDA advisory committee
[Chancellor’s Professor] Daniel Gillen, Ph.D., from the department of statistics at the University of California, Irvine set out the case against VERU-111, also known as sabizabulin. “Given the data that we have currently, I believe we have a limited both efficacy and safety data set with a new molecule where we don’t have a full understanding of the mechanism of action,” Gillen said. “I don’t know if we’re ever guaranteed to know that completely, but certainly we’re far from it at this point.” Gillen voted no.
